Want to see IL:BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
371.40
-0.16(-2.50%)
At close: 4:00 PM EST
371.40
-0.16(-2.50%)
Day’s Range― - ―
52-Week Range209.20 - 564.80
Previous CloseN/A
Volume1.67K
Average Volume (3M)11.86K
Market Cap
₪38.32M
Enterprise Value16.64M
Total Cash (Recent Filing)₪23.65M
Total Debt (Recent Filing)₪772.00K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding9,079,270
10 Day Avg. Volume7,448
30 Day Avg. Volume11,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt materially reduces refinancing and short-term solvency risk, giving management flexibility to fund R&D or bridge financing without large interest burdens. That structural debt conservatism supports continuity even amid operating losses over the medium term.
Lean Operating FootprintA tiny headcount implies a low fixed-cost base and operational agility typical of pre-commercial medical-specialty firms. This structural lean profile helps conserve cash, extend runway between financings, and focuses spend on R&D rather than large SG&A overheads.
R&D-Heavy, Pre-Commercial ModelPersistent investment in R&D signals a pipeline-driven strategy; if clinical or regulatory milestones are achieved this can create enduring product advantages in medical specialties. The structural focus on innovation can underpin future revenue and competitive differentiation.
Bears Say
Revenue CollapseThe absence of recurring revenue removes a reliable cash foundation and indicates the business has not yet scaled commercial operations. Over the medium term this elevates reliance on financing and increases execution risk for translating R&D into sustainable sales.
Persistent Cash BurnConsistently negative operating and free cash flow show losses translate into real cash outflows, not just non-cash charges. Structurally negative cash generation necessitates repeated external funding and constrains strategic optionality over the coming months without decisive revenue traction.
Eroding Equity CushionMaterial decline in shareholder equity over several years reflects cumulative losses and reduces the capital buffer versus adverse events. A shrinking equity base limits absorption of further losses, raises solvency concerns longer term, and increases likelihood of dilutive capital raises.
BOLT FAQ
What was BioLight Life Sciences Ltd.’s price range in the past 12 months?
BioLight Life Sciences Ltd. lowest stock price was 209.20 and its highest was 564.80 in the past 12 months.
What is BioLight Life Sciences Ltd.’s market cap?
BioLight Life Sciences Ltd.’s market cap is ₪38.32M.
When is BioLight Life Sciences Ltd.’s upcoming earnings report date?
BioLight Life Sciences Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 27 days.
How were BioLight Life Sciences Ltd.’s earnings last quarter?
BioLight Life Sciences Ltd. released its earnings results on Apr 01, 2026. The company reported -61.9 earnings per share for the quarter, missing the consensus estimate of N/A by -61.9.
Is BioLight Life Sciences Ltd. overvalued?
According to Wall Street analysts BioLight Life Sciences Ltd.’s price is currently Overvalued.
Does BioLight Life Sciences Ltd. pay dividends?
BioLight Life Sciences Ltd. does not currently pay dividends.
What is BioLight Life Sciences Ltd.’s EPS estimate?
BioLight Life Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioLight Life Sciences Ltd. have?
BioLight Life Sciences Ltd. has 9,079,270 shares outstanding.
What happened to BioLight Life Sciences Ltd.’s price movement after its last earnings report?
BioLight Life Sciences Ltd. reported an EPS of -61.9 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioLight Life Sciences Ltd.?
Currently, no hedge funds are holding shares in IL:BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLight Life Sciences Ltd.
BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include DiagnosTear's TeaRx, a diagnostic platform analyzing tear fluid components to identify frontal eye diseases, and Peripherex, offering solutions for both at-home and clinical diagnosis and monitoring of peripheral vision loss, crucial for conditions like glaucoma. For glaucoma, BioLight features ViSci (an Eye D technology utilizing a subconjunctival implant), Belkin Vision's rapid, automated laser system for effective intraocular pressure reduction, and Sanoculis, which is advancing a novel surgical approach. The company also encompasses OphRx, focused on developing pharmaceutical treatments for ocular disorders; AEYE, which designs artificial intelligence-powered solutions for diverse retinal conditions; and Tarsier, working on TRS 01, a platform-based treatment for uveitis in patients with elevated intraocular pressure. Founded in 2005, the Tel Aviv, Israel-based company operated as Bio Light Israeli Life Sciences Investments Ltd. until its rebranding to BioLight Life Sciences Ltd. in February 2016.